A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward

NCT00605241 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Substance Dependence

Interventions

DRUG: GSK598809

Sponsor

GlaxoSmithKline